logo
Plus   Neg
Share
Email

NRG Announces Asset Sales Incl. Sale Of Interest In NRG Yield; $2.8 Bln Proceeds

NRG Energy, Inc. (NRG) and Global Infrastructure Partners have entered into a purchase agreement for GIP to purchase NRG's ownership in NRG Yield and NRG's Renewables Platform for cash proceeds of $1.375 billion. NRG and NRG Yield entered into Purchase and Sale Agreements for NRG Yield to purchase NRG's interest in the ROFO pipeline assets: 527 MW Carlsbad Energy Center and 154 MW Buckthorn Solar, for additional cash proceeds of $407 million. NRG and Cleco Corporate Holdings LLC entered into a Purchase and Sale Agreement for Cleco to purchase NRG's South Central business for a total purchase price and cash proceeds of $1.0 billion.

The announcement brings NRG's cumulative Transformation Plan asset sales to $2.9 billion in anticipated cash proceeds, including approximately $150 million of asset monetization closed in the second half of 2017. NRG expects to announce additional asset sales over the course of 2018 and revised its total asset sales cash proceeds target to approximately $3.2 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Automaker Ford Motor Co. and retail giant Walmart said Wednesday that they are collaborating to explore delivery of grocery and other goods using self-driving vehicles. The companies will partner with San Francisco-based delivery service Postmates to design a service for autonomous-vehicle delivery of goods. Walmart noted that in Miami, Postmates already serves as it's delivery partner. Financial services firm American Express or Amex has filed a patent for a blockchain-based system that can match the images of a receipt with stored records. According to a U.S. Patent and Trademark Office or USPTO patent filing, named "Linking digital images with related records", the system offers a new method to receive, record and transmit images of receipts. Merck KGaA reported Wednesday a sharp decline in its third-quarter profit, while sales increased despite negative currency impacts. Further, the German drugmaker lowered its fiscal 2018 forecast for EBITDA pre, but confirmed organic EBITDA pre view. The company also lifted its organic net sales growth forecast.
Follow RTT